Orthogonal transcriptional modulation and gene editing using multiple CRISPR-Cas systems
Molecular Therapy · 2025-01 · 33 (1) · 71-89
DOI: 10.1016/j.ymthe.2024.11.024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2025-01. Verfasst von Amalie Dyrelund Broksø und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedicine, Aarhus University, Aarhus C, Denmark. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Gene Editing, RNA, Guide, CRISPR-Cas Systems, Streptococcus pyogenes. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HORIZON EUROPE European Research Council, European Innovation Council, Innovation Fund Denmark.
Abstract (Originalsprache)
CRISPR-Cas-based transcriptional activation (CRISPRa) and interference (CRISPRi) enable transient programmable gene regulation by recruitment or fusion of transcriptional regulators to nuclease-deficient Cas (dCas). Here, we expand on the emerging area of transcriptional engineering and RNA delivery by benchmarking combinations of RNA-delivered dCas and transcriptional modulators. We utilize dCas9 from Staphylococcus aureus and Streptococcus pyogenes for orthogonal transcriptional modulation to upregulate one set of genes while downregulating another. We also establish trimodal genetic engineering by combining orthogonal transcriptional regulation with gene knockout by Cas12a (Acidaminococcus; AsCas12a) ribonucleoprotein delivery. To simplify trimodal engineering, we explore optimal parameters for implementing truncated single guide RNAs (sgRNAs) to make use of SpCas9 for knockout and CRISPRa. We find the Cas9 protein/sgRNA ratio to be crucial for avoiding sgRNA cross-complexation and for balancing knockout and activation efficiencies. We demonstrate high efficiencies of trimodal genetic engineering in primary human T cells while preserving basic T cell health and functionality. This study highlights the versatility and potential of complex genetic engineering using multiple CRISPR-Cas systems in a simple one-step process yielding transient transcriptome modulation and permanent DNA changes. We believe such elaborate engineering can be implemented in regenerative medicine and therapies to facilitate more sophisticated treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedicine, Aarhus University, Aarhus C, Denmark.
- Department of Biomedicine, Aarhus University, Aarhus C, Denmark. Electronic address: bak@biomed.au.dk.
Förderung
- HORIZON EUROPE European Research Council
- European Innovation Council
- Innovation Fund Denmark
- Agnes and Poul Friis Fund
- European Health and Digital Executive Agency
- European Commission
- Society for the Study of Theology
- Aarhus Universitet
Zitieren
APA
Broksø, A. D., Bendixen, L., Fammé, S., Mikkelsen, K., Jensen, T. I., & Bak, R. O. (2025). Orthogonal transcriptional modulation and gene editing using multiple CRISPR-Cas systems. Molecular Therapy, 33(1), 71-89. https://doi.org/10.1016/j.ymthe.2024.11.024
Vancouver
Broksø AD, Bendixen L, Fammé S, Mikkelsen K, Jensen TI, Bak RO. Orthogonal transcriptional modulation and gene editing using multiple CRISPR-Cas systems. Molecular Therapy. 2025;33(1):71-89. doi:10.1016/j.ymthe.2024.11.024
BibTeX
@article{Broks2025,
author = {Broksø, Amalie Dyrelund and Bendixen, Louise and Fammé, Simon and Mikkelsen, Kasper and Jensen, Trine Ilsø and Bak, Rasmus O},
title = {Orthogonal transcriptional modulation and gene editing using multiple CRISPR-Cas systems},
journal = {Molecular Therapy},
year = {2025},
volume = {33},
number = {1},
pages = {71--89},
doi = {10.1016/j.ymthe.2024.11.024}
}
EUVIMED